# A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions

> **NCT05666518** · — · RECRUITING · sponsor: **Bayer** · enrollment: 1400 (estimated)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** Vericiguat (Verquvo, BAY1021189)
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT05666518
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 1400 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05666518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05666518, "A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT05666518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*